## US Family Health Plan Prior Authorization Request Form for risankizumab (Skyrizi)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD. Humira is the Department of Defense's preferred targeted biologic agent for FDA approved indications.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Step	Please complete patient and physician information (please print):				
1	Patient Name:	Physician Name:			
	Address:	Address:			
	Sponsor ID #	Phone #:			
	Date of Birth:	Secure Fax #:			
Step 2	Please complete the clinical assessment:				
	Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	□ Yes	□ No		
		proceed to question 2	proceed to question 4		
	2. Has the patient had an inadequate response to Humira?	☐ Yes	□ No		
		proceed to question 5	proceed to question 3		
	3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	1 103	□ No STOP		
		proceed to question 5	Coverage not approved		
	4. Does the patient have a contraindication to Humira (adalimumab)?	□ Yes	□ No		
		proceed to question 5	STOP		
			Coverage not approved		
	5. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Cosentyx (secukinumab)?	e □ Yes	□ No		
		proceed to question 6	STOP		
			Coverage not approved		
	6. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Stelara (ustekinumab)?	e □ Yes	□ No		
		proceed to question 7	STOP		
			Coverage not approved		

Continue on next page

## USFHP Prior Authorization Request Form for risankizumab (Skyrizi)

	7. Is the patient 18 years of age or older?	☐ Yes	□ No
		proceed to question 8	STOP
			Coverage not approved
	8. What is the indication or diagnosis?	☐ Moderate to severe plaque psoriasis who is a candidate for phototherapy or systemic therapy - proceed to question <b>9</b>	
		☐ Active psoriatic arthritis (Ps	A) - proceed to question <b>9</b>
		☐ Other - STOP Coverage not approved	
	<ol><li>Has the patient had an inadequate response to non- biologic systemic therapy? (For example:</li></ol>	□ Yes	□ No
	methotrexate, aminosalicylates [for example,	proceed to question 10	STOP
	sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example, azathioprine], etc.)		Coverage not approved
	10. Does the patient have evidence of a negative TB test	☐ Yes	□ No
	result in the past 12 months (or TB is adequately managed)?	proceed to question 11	STOP
			Coverage not approved
	11. Will the patient be receiving other targeted immunomodulatory biologics with the requested medication, including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz, or Xeljanz/Xeljanz XR?	☐ Yes STOP Coverage not approved	□ No Sign and date below
Step		. D	
<b>3</b>	I certify the above is true to the best of my knowledge.	<b>edge.</b> Please sign and da	te:
	Prescriber Signature	Date	
			[29 June 2022]